NuvOx Therapeutics, Inc. (NUOX)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	91.67M
Revenue (ttm)	1.04M +91.4%
Net Income	-11.81M
EPS	-0.90
Shares Out	13.10M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About NUOX

NuvOx Therapeutics is a clinical-stage biopharmaceutical company developing innovative oxygen therapeutic solutions for the treatment of diseases where hypoxia, or lack of oxygen, plays a critical role. Our product candidate is NanO2, the API of which is dodecafluoropentane. NanO2 is administered intravenously as an emulsified liquid, containing nano-sized droplets that after entering the body, due to the human body temperature, convert to a gas, which enables them to deliver more oxygen than when in the liquid state. The focus of our clinical ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 9
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: NUOX
• Website: https://www.nuvoxtherapeutics.com/

Financial Performance

Financial numbers in USD

Data Source: SEC filings Last updated: Aug 20, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error